Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Approval
Sort By
Newest First
1 / 2
Anixa Biosciences
Approval
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences
PR-02-25-NI-16
Feb 19, 2025
Oncolytics Biotech
Clinical CRO
Regulatory Approval Clears Path for Oncolytics Biotech to Pancreatic Cancer Treatment
Oncolytics Biotech
PR-01-25-NI-18
Jan 16, 2025
Biohaven
Migraine
Biohaven Announces NURTEC® ODT Receives First Global Approval Outside the U.S. For Prevention of Migraine
Biohaven
PR-M12-21-01
Dec 13, 2021
AstraZeneca
Drug Approval
Farxiga Approved in the US for the Treatment of Heart Failure in Patients
AstraZeneca
PR-M05-20-NI-015
May 08, 2020
Merck & Co.
Drug Development
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
Merck & Co.
PR-M01-20-NI-003
Jan 02, 2020
AstraZeneca
Drug Approval
Calquence Approved in the US for Adult Patients with Chronic Lymphocytic Leukemia
AstraZeneca
PR-M11-19-NI-037
Nov 25, 2019
Drug Approval
Qtrilmet Approved in the EU for the Treatment of Type-2 Diabetes
Nice Insight
PR-M11-19-NI-020
Nov 19, 2019
Merck & Co.
Vaccine Approval
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Merck & Co.
PR-M11-19-NI-011
Nov 13, 2019
Novartis
Approval
Novartis Gets European Approval to Update Cosentyx Label to Include Dosing Flexibility in Ankylosing Spondylitis
Novartis
PR-M10-19-NI-036
Oct 25, 2019
AstraZeneca
Approval
Farxiga Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type-2 Diabetes
AstraZeneca
PR-M10-19-NI-029
Oct 22, 2019
Janssen Pharmaceutical Companies
FDA Approval
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Janssen Pharmaceutical Companies
PR-M10-19-NI-032-2050
Oct 22, 2019
Glenmark Pharmaceuticals
Approval
Glenmark Receives Approval for Combination of Remogliflozin Etabonate and Metformin Hydrochloride for Adults With Type 2 Diabetes in India
Glenmark Pharmaceuticals
PR-M08-19-NI-067
Aug 23, 2019
Alcon
Launch
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses as it Continues to Deliver on Vision Care Pipeline
Alcon
PR-M08-19-NI-053
Aug 20, 2019
Eli Lilly and Company
FDA Fast Track
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Eli Lilly and Company
PR-M06-19-NI-058
Jun 28, 2019
Drug Approval
Emflaza Now Approved for Treatment of Young Children
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M06-19-NI-011
Jun 20, 2019
FDA Approval
FDA Approves First Anticoagulant Blood Thinner for Use in Children
Pharma's Almanac
PAO-M05-19-NI-028
May 29, 2019
Approval
Triple Combination Treatments for Multiple Myeloma Approved in Europe
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M05-19-NI-027
May 29, 2019
Abbott
Prequalification Approval
Abbott Receives WHO Prequalification Approval for Breakthrough HIV Point-of-Care Test
Abbott
PR-M05-19-NI-017
May 06, 2019
Approval
Roche Gets New EU Approval for MabThera
Pharma's Almanac
PAO-M03-19-NI-027
Mar 20, 2019
Approval
European Commission Approved Tecentriq/Avastin Combination Therapy for Lung Cancer
Pharma's Almanac
PAO-M03-19-NI-018-2902
Mar 12, 2019
1 / 2
